SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20160326125A1
公开(公告)日:2016-11-10
The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used medicaments.
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
本公开提供了具有MASP-2抑制活性的化合物,这些化合物的组合物,以及制造和使用这些化合物的方法。
Tuning chemoselectivity in <i>O</i>-/<i>N</i>-arylation of 3-aryl-1,2,4-oxadiazolones with <i>ortho</i>-(trimethylsilyl)phenyl triflates <i>via</i> aryne insertion
作者:Lijing Zhou、Hongji Li、Wenge Zhang、Lei Wang
DOI:10.1039/c8cc00124c
日期:——
A finely tunable chemoselectivity in arylation of 3-aryl-1,2,4-oxadiazolones with ortho-(trimethylsilyl)phenyl triflates is reported, including silver-catalysed O-arylation and metal-free N-arylation.
Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure:
where the definitions of the variables are provided herein.
Formula I的Chroman化合物和衍生物是TRPM8的有用抑制剂。这些化合物在治疗多种由TRPM8介导的疾病和症状方面具有用途,并可用于制备治疗这些疾病和症状的药物和药物组合物。这些疾病的例子包括,但不限于,偏头痛和神经病性疼痛。Formula I的化合物具有以下结构:变量的定义在此提供。
TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
申请人:BROWN James
公开号:US20130158034A1
公开(公告)日:2013-06-20
Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure:
where the definitions of the variables are provided herein.